If responses are inadequate at lower doses, a higher daily dose of Keppra (2000 mg/3000 mg) may lead to a better response2
Patients (%) experiencing reductions of ≥50% or 100% in seizure frequency vs baseline with various doses of LEV and placebo2
Anoro Ellipta 20 mcg
has been lorem added to your basket
Efficacy in adults ≥ 16 years
Keppra as a monotherapy demonstrated comparable rates of seizure freedom to carbamazepine CR in adult patients with focal epilepsy1
Seizure freedom rates in adults (≥16 years) on levetiracetam or carbamazepine CR1
Randomised, double-blind, parallel-group, comparator-controlled monotherapy trial.
Primary objective was to demonstrate that monotherapy with LEV (1000 to 3000 mg/day) (n=288) was non-inferior to monotherapy with CBZ CR (400 to 1200 mg/day) (n=291) in adults (≥16 years) with newly diagnosed epilepsy.1
The same results were first published in Brodie MJ, et al. Neurology 2007;68:402–408. The graph has been independently created by GSK from the original data.
Safety information: A similar proportion of patients in the Keppra (79.6%) and CBZ CR groups (80.8%) experienced at least one adverse event during the treatment period.
Keppra reduced seizure frequency in children with treatment-resistant focal epilepsy vs placebo, used adjunctively3
Median percentage reduction from baseline in weekly focal seizure frequency during treatment (14 weeks) in children aged 4–16 years3
Multicentre, randomised, placebo-controlled trial that evaluated the efficacy and tolerability of LEV as adjunctive therapy in children aged 4–16 years (n=198) with treatment-resistant focal seizures. It consisted of an 8-week baseline period followed by a 14-week double-blind treatment period. During the treatment period, patients received either placebo or LEV add-on therapy and were up-titrated to a target dose of 60 mg/kg/day.3
The same results were first published in Glauser TA, et al. Neurology 2006;66:1654–1660. The graph has been independently created by GSK from the original data.
Visit our Resources page for more information
AED: anti-epileptic drug; CBZ: carbamazepine; CI: confidence interval; CR: controlled release; LEV: levetiracetam; SD: study design.
GSK shall not be liable for any damages, claims, liabilities, costs or obligations arising from the use or misuse of information provided herein.
For safety information on GSK products or to report an Adverse Event, please contact the toll free line
0800 CALL GSK (0800 2255 475) or email firstname.lastname@example.org
Full prescribing information is available on request on www.gskpro.com
Please note that it may take up to 10 days to process your request. If you need further assistance contact
GSK House, 1 Industrial Avenue llupeju, Lagos or via email at email@example.com
GlaxoSmithKline Pharmaceutical Nigeria Ltd, 1 Industrial Avenue, llupeju, Lagos 234-1-271 1000
©2020 GSK group of companies or its licensor
Trade marks are owned by or licensed to the GSK group of companies
Keppra is a registered trademark of the GlaxoSmithKline group of companies
PM-NG-LVT-WCNT-200004 Date of preparation: November 2020.